<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02490527</url>
  </required_header>
  <id_info>
    <org_study_id>UCSD IRB</org_study_id>
    <nct_id>NCT02490527</nct_id>
  </id_info>
  <brief_title>Effects of Epicatechin on Statins for Mitochondrial Dysfunction and Impaired Exercise Capacity</brief_title>
  <official_title>Effects of Epicatechin on Patients With Statin-induced Mitochondrial Dysfunction and Impaired Exercise Capacity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Heart Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to gain insight into the side-effects of statin consumption, and
      assess the ability of epicatechin (a compound in dark chocolate) to counteract or reverse
      these changes. The investigators' prior research has shown that epicatechin can improve
      skeletal muscle structure and mitochondrial (which gives us energy) structure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patient Inclusion Criteria:

        1. Must be between 30-75 years of age.

        2. Must have a VO2max greater than 25 ml/kg/min(non-sedentary individuals).

        3. Subjects with LDL&gt;100mg/dL

        4. Subjects without a prior cerebrovascular event (example: stroke)

        5. Subjects without a prior cardiovascular event (example: heart attack)

      Patient Exclusion Criteria:

        1. Liver, thyroid, or kidney disease.

        2. Currently taking drugs that interfere with statin metabolism (calcium channel blockers,
           colchicine etc.).

        3. Acute or chronic infectious disease; autoimmune/inflammatory disease, cancer, COPD,
           anemia, diabetes, psychiatric illness.

        4. Non-smokers, prior smokers, or illicit drug users with abstinence &gt;1 year.

        5. Subjects taking blood thinners (Coumadin, xarelto, pradaxa, Plavix, effient, epixiban
           etc) will be excluded. If subjects are taking aspirin for routine prevention they will
           be asked to hold aspirin for 7 days prior to biopsy. Routine prevention means that the
           patients are taking aspirin to reduce their risks, but do not have established
           cardiovascular disease.

        6. History of previous knee surgery and active history of knee pain or neuromuscular
           disease are exclusions as they are known to affect muscle structure and function.

      The study will be a double blind placebo controlled study where subjects will be randomized
      to either of two groups:

        1. Simvastatin 40 mg + placebo once daily (statin only group) for 3 months

        2. Simvastatin 40 mg + Epi 50 mg once daily (statin + Epi group) for 3 months
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Functional Capacity</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <description>Cardiopulmonary exercise protocol will be used to measure VO2max to assess functional capacity.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Composite Outcome: Changes in Skeletal Muscle Structure and Protein Levels</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <description>Skeletal muscle biopsies will be examined by electron microscopy to determine change in skeletal muscle structure. Western blots will be done to look for changes in protein levels.</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in Blood-Based Biomarkers</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <description>Biomarker levels in the blood will be evaluated for correlation with changes in the skeletal muscle mitochondrial structure and function.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Statin Intolerance</condition>
  <arm_group>
    <arm_group_label>Statin only</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The subject will consume simvastatin (40mg) and placebo once daily for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Statin and epicatechin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The subject will consume simvastatin (40mg) and pure epicatechin capsules (50mg) once daily for 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Pure epicatechin capsules (50mg)</intervention_name>
    <description>Epicatechin is a compound found naturally in dark chocolate.</description>
    <arm_group_label>Statin and epicatechin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin (40mg)</intervention_name>
    <description>A cholesterol-lowering medication that blocks the production of cholesterol.</description>
    <arm_group_label>Statin only</arm_group_label>
    <arm_group_label>Statin and epicatechin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A substance that has no therapeutic effect and will act as a control.</description>
    <arm_group_label>Statin only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Patient Inclusion Criteria:

          -  Must be between 30-75 years of age

          -  LDL&gt;100mg/dL

          -  VO2 max greater than 25 ml/kg/min

        Patient Exclusion Criteria:

          -  Liver or kidney disease

          -  Currently taking drugs that interfere with statin metabolism

          -  Currently taking blood thinners

          -  Acute or chronic infectious disease; autoimmune/inflammatory disease, cancer, COPD,
             anemia, psychiatric illness, insulin-dependent diabetes

          -  smokers or illicit drug users

          -  adverse cardiovascular event (ex: heart attack)

          -  history of knee surgery or active history of knee pain
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pam Taub, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hannah Lo, B.S.</last_name>
    <phone>858-246-2510</phone>
    <email>ucsdresearchcoordinator@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pam Taub, M.D.</last_name>
    <email>ptaub@ucsd.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Pam Taub, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Taub PR, Ramirez-Sanchez I, Ciaraldi TP, Perkins G, Murphy AN, Naviaux R, Hogan M, Maisel AS, Henry RR, Ceballos G, Villarreal F. Alterations in skeletal muscle indicators of mitochondrial structure and biogenesis in patients with type 2 diabetes and heart failure: effects of epicatechin rich cocoa. Clin Transl Sci. 2012 Feb;5(1):43-7. doi: 10.1111/j.1752-8062.2011.00357.x. Epub 2011 Nov 7.</citation>
    <PMID>22376256</PMID>
  </reference>
  <reference>
    <citation>Yamazaki KG, Taub PR, Barraza-Hidalgo M, Rivas MM, Zambon AC, Ceballos G, Villarreal FJ. Effects of (-)-epicatechin on myocardial infarct size and left ventricular remodeling after permanent coronary occlusion. J Am Coll Cardiol. 2010 Jun 22;55(25):2869-76. doi: 10.1016/j.jacc.2010.01.055.</citation>
    <PMID>20579545</PMID>
  </reference>
  <reference>
    <citation>Nogueira L, Ramirez-Sanchez I, Perkins GA, Murphy A, Taub PR, Ceballos G, Villarreal FJ, Hogan MC, Malek MH. (-)-Epicatechin enhances fatigue resistance and oxidative capacity in mouse muscle. J Physiol. 2011 Sep 15;589(Pt 18):4615-31. doi: 10.1113/jphysiol.2011.209924. Epub 2011 Jul 25.</citation>
    <PMID>21788351</PMID>
  </reference>
  <reference>
    <citation>Ramirez-Sanchez I, Nogueira L, Moreno A, Murphy A, Taub P, Perkins G, Ceballos GM, Hogan M, Malek M, Villarreal F. Stimulatory effects of the flavanol (-)-epicatechin on cardiac angiogenesis: additive effects with exercise. J Cardiovasc Pharmacol. 2012 Nov;60(5):429-38. doi: 10.1097/FJC.0b013e318269ae0d.</citation>
    <PMID>22833114</PMID>
  </reference>
  <reference>
    <citation>Ramirez-Sanchez I, Taub PR, Ciaraldi TP, Nogueira L, Coe T, Perkins G, Hogan M, Maisel AS, Henry RR, Ceballos G, Villarreal F. (-)-Epicatechin rich cocoa mediated modulation of oxidative stress regulators in skeletal muscle of heart failure and type 2 diabetes patients. Int J Cardiol. 2013 Oct 9;168(4):3982-3990. doi: 10.1016/j.ijcard.2013.06.089. Epub 2013 Jul 17.</citation>
    <PMID>23870648</PMID>
  </reference>
  <reference>
    <citation>Taub PR, Ramirez-Sanchez I, Ciaraldi TP, Gonzalez-Basurto S, Coral-Vazquez R, Perkins G, Hogan M, Maisel AS, Henry RR, Ceballos G, Villarreal F. Perturbations in skeletal muscle sarcomere structure in patients with heart failure and type 2 diabetes: restorative effects of (-)-epicatechin-rich cocoa. Clin Sci (Lond). 2013 Oct;125(8):383-9. doi: 10.1042/CS20130023.</citation>
    <PMID>23642227</PMID>
  </reference>
  <reference>
    <citation>Barnett CF, Moreno-Ulloa A, Shiva S, Ramirez-Sanchez I, Taub PR, Su Y, Ceballos G, Dugar S, Schreiner G, Villarreal F. Pharmacokinetic, partial pharmacodynamic and initial safety analysis of (-)-epicatechin in healthy volunteers. Food Funct. 2015 Mar;6(3):824-33. doi: 10.1039/c4fo00596a.</citation>
    <PMID>25598082</PMID>
  </reference>
  <reference>
    <citation>Ortiz-Vilchis P, Yamazaki KG, Rubio-Gayosso I, Ramirez-Sanchez I, Calzada C, Romero-Perez D, Ortiz A, Meaney E, Taub P, Villarreal F, Ceballos G. Co-administration of the flavanol (-)-epicatechin with doxycycline synergistically reduces infarct size in a model of ischemia reperfusion injury by inhibition of mitochondrial swelling. Eur J Pharmacol. 2014 Dec 5;744:76-82. doi: 10.1016/j.ejphar.2014.09.042. Epub 2014 Oct 2.</citation>
    <PMID>25281837</PMID>
  </reference>
  <reference>
    <citation>Gutierrez-Salmean G, Ciaraldi TP, Nogueira L, Barboza J, Taub PR, Hogan MC, Henry RR, Meaney E, Villarreal F, Ceballos G, Ramirez-Sanchez I. Effects of (-)-epicatechin on molecular modulators of skeletal muscle growth and differentiation. J Nutr Biochem. 2014 Jan;25(1):91-4. doi: 10.1016/j.jnutbio.2013.09.007. Epub 2013 Oct 18.</citation>
    <PMID>24314870</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 17, 2015</study_first_submitted>
  <study_first_submitted_qc>July 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 7, 2015</study_first_posted>
  <last_update_submitted>March 5, 2018</last_update_submitted>
  <last_update_submitted_qc>March 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Pam Taub, MD</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>myopathy</keyword>
  <keyword>muscular weakness</keyword>
  <keyword>cramping</keyword>
  <keyword>fatigue</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

